The specific aim of this project was engineering of molecules capable of redirecting, accelerating, and amplifying immunity from the preventive immunity, attained due to HBsAg vaccination against HBVs, towards the therapeutic immunity against HER-2+ ovarian cancers. Here, ERBB2 is linked to ovarian carcinoma.